

Docket No.: NIH147.001D1

October 27, 2005

App. No.: 10/057,113

Page 1 of 2

Customer Number 45311

TERMINAL DISCLAIMER UNDER 37 CFR § 1.321

Applicant : Szkudlinski et al.
App. No : 10/057,113
Filed : January 25, 2002
For : GLYCOPROTEIN HORMONE
SUPERAGONISTS
Examiner : Spector, Lorraine
Art Unit : 1647

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Right of Assignee and Ownership

In accordance with 37 C.F.R. § 3.73(b), Assignee represents that it is the owner of a 100 percent interest in the above-identified application and co-owned, Patent No. 6,361,992, all by virtue of an assignment recorded at Reel No. 9789, Frame No. 0086 by the Assignment Branch of the Patent and Trademark Office. The Assignee represents that, to the best of Assignee's knowledge and belief, title is in the Assignee seeking to take action.

Disclaimer by Assignee

Assignee, The Government of the United States of America as represented by the Secretary, Department of Health and Human Services ("Assignee"), hereby disclaims, except as provided below, the terminal part of any patent granted on the above-referenced application which would extend beyond the expiration date of the full statutory term of U.S. Patent No. 6,361,992, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the above-identified application and U.S. Patent No. 6,361,992 are co-owned. This agreement extends to any patent granted on the above-referenced application and shall be binding on its successors or assigns.

Docket No.: NIH147.001D1
App. No.: 10/057,113

October 27, 2005
Page 2 of 2

Customer Number 45311

Assignee does not disclaim any terminal part of any patent granted on the above-referenced application prior to the earlier of the expiration date of the full statutory term of U.S. Patent No. 6,361,992, and that of any patent issuing on the above-identified application in the event that either one later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to expiration of its full statutory term, except for the separation of legal title stated above.

This Terminal Disclaimer is accompanied by the \$130 fee set forth in 37 C.F.R. § 1.20(d).
Done on this _____ day of October, 2005, at Rockville, Maryland.

UNITED STATES DEPARTMENT OF HEALTH
AND HUMAN SERVICES

By: Marlene Astor

Printed Name: Marlene Astor

Registration No.: 46,005

for:
Office of Technology Transfer
National Institutes of Health
6011 Executive Boulevard, Suite 325
Rockville, MD 20852
Telephone (301) 496-7056
Facsimile (301) 402-0220